Lilly's retatrutide lawsuits: what the dockets say

Between 12 August and 8 October 2026, Eli Lilly filed eleven lawsuits against businesses it says are selling retatrutide, its investigational obesity molecule, before any regulator has approved it. The press coverage ran to a few paragraphs: a drug maker, a black market, six companies, then five more. The court record is a good deal more interesting than that, and this piece reads it in full: what Lilly pleaded and what it did not, what has happened on each docket since, where the legal theory is strong and where it is open, and what the cases will actually turn on.

Facts below are cited to the filings; the questions are ours.

The record

Lilly announced the first wave on 12 August 2026: six suits, in four federal districts, against a compounding pharmacy near Houston, a medical spa chain in California, and four online sellers in Texas whose websites described their products as for research use. On 8 October it filed five more: three online sellers (in Louisiana and Texas), an Arizona weight-management clinic, and a Texas medical practice. The same statement announced that Lilly had referred more than 200 individuals and entities to FDA, the Department of Justice, state attorneys general and licensing boards, and had identified 14,000-plus websites, advertisements, social media posts and product listings in more than 100 countries.

We refer to the cases by court and docket number, and to the defendants by what they are rather than by name, as we do throughout this library.

Lilly's eleven suits, and where each stood on 26 October 2026

Filed	Court and docket	Defendant	Claims	Status
12 Aug 2026	S.D. Tex., 4:26-cv-06563	Compounding pharmacy (503A), Katy, Texas	Eight states' unfair-competition and consumer-protection laws	Defending. Service waived; the parties told the court on 5 October that they are in settlement discussions; response to the complaint due 30 October; a scheduling order runs to expert reports in April 2027
12 Aug 2026	E.D. Cal., 2:26-cv-02764	Medical spa chain, Sacramento	Lanham Act false advertising	Dismissed by Lilly with prejudice on 11 September, before any response was filed
12 Aug 2026	E.D. Tex., 1:26-cv-00347	Online seller, Lumberton, Texas	Eight states' laws	Contested. Motion to dismiss filed 2 October for lack of standing and failure to state a claim; Lilly's response due in mid-November; case management conference 30 November
12 Aug 2026	S.D. Tex., 4:26-cv-06562	Online seller, Houston	Eight states' laws	Defendant never appeared. On 11 September Lilly told the court it would move for default judgment; on 16 October it dismissed the case with prejudice instead
12 Aug 2026	W.D. Tex., 5:26-cv-05146	Online seller, Houston	Eight states' laws	Dismissed by Lilly with prejudice on 15 October, before any response was filed
12 Aug 2026	W.D. Tex., 5:26-cv-05147	Online seller, Austin	Eight states' laws	Lilly amended on 31 August to add a defendant whose true legal identity is presently unknown, filed a notice of voluntary dismissal on 2 September, and on 30 September asked the court for discovery before service to find out who operates the website
8 Oct 2026	W.D. La., 5:26-cv-04146	Online seller	Eight states' laws	Complaint filed
8 Oct 2026	S.D. Tex., 4:26-cv-08806	Online seller	Eight states' laws	Complaint filed
8 Oct 2026	N.D. Tex., 3:26-cv-03514	Online seller (an individual)	Eight states' laws	Complaint filed
8 Oct 2026	D. Ariz., 2:26-cv-07361	Weight-management clinic	Lanham Act false advertising	Complaint filed
8 Oct 2026	N.D. Tex., 4:26-cv-01294	Medical practice and spa	Lanham Act false advertising	Complaint filed

Eleven weeks after the first filings, no court has ruled on anything. Three cases are over because Lilly ended them. One defendant is being looked for. One is negotiating. One is fighting. Five are too new to have moved.

What Lilly pleads, and what it does not

Against the online sellers, every complaint has the same shape. There is no claim under the federal Food, Drug, and Cosmetic Act, because that statute gives no private right of action: only the United States may enforce it. There is no patent claim, although Lilly holds patents on the molecule. There is no trademark claim, because retatrutide is a non-proprietary name that no one owns. Instead there are eight counts under the unfair-competition and consumer-protection laws of Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee, Texas and Washington. Each count works the same way: the state has its own statute forbidding the sale of a new drug without federal approval; selling retatrutide breaks it; breaking it is an unfair or deceptive practice; and Lilly, as a competitor, may sue for that.

Against the clinics and the medical spa, Lilly pleads something different: a single count of false advertising under section 43(a) of the Lanham Act, aimed at their statements about clinical-trial support, approval status and comparisons with approved medicines.

The relief sought is the same everywhere: a permanent injunction against making, marketing or selling anything containing or purporting to contain retatrutide, disgorgement of profits, damages, and attorneys' fees. The Texas count adds exemplary damages. The compounding-pharmacy complaint runs to forty pages; Lilly's lawyers are from Kirkland & Ellis.

The complaints are candid about the molecule's status. The pharmacy complaint says retatrutide is legally available only under strict protocols to select patients as an investigational new drug, and that Lilly has not finished its clinical trials or submitted a final data package to FDA. Its first paragraph puts the point in one sentence:

Retatrutide cannot legally be sold for human use to anyone, anywhere, for any reason.

That sentence is the foundation of Lilly's case. It is also, as we will see, the foundation of the defense.

What is not in dispute

Before the questions, the things we think are settled, because a piece like this earns the right to ask hard questions only by conceding the easy answers.

• The molecule is unapproved, and there is no lawful route to sell it for human use. FDA said on 15 June 2026 that retatrutide and cagrilintide cannot be used in compounding under federal law, and that neither is a component of an approved drug. There is no shortage exemption, no bulk-substance listing, no monograph. A compounding pharmacy making it has no statutory footing at all.
• A research-use label describes intent; it does not create a safe harbor. This library's enforcement tracker records FDA's warning letters to research-labeled sellers, fourteen of which name this molecule, and every one finds intended use from the rest of the website: calculators, kits, solvent sold alongside, comparison claims. Lilly's complaints do the same work with the same kinds of evidence. One quotes a seller's calculator page: Enter the vial strength, the bacteriostatic water you added, and your target dose. Where a complaint quotes that kind of material, the label will not save the seller, and we would not argue that it should.
• Lilly's concern is not invented. On 13 October 2026, CBS News reported two deaths submitted to FDA's adverse-event system in July and September, each involving a product represented as retatrutide bought outside any trial. The reports are unverified, FDA declined to say whether it had confirmed them, and the products were never analyzed, so no one can say what was in the vials. That uncertainty is the point. Poison-control centers logged 862 exposures to the compound in the quarter to September, up from 249 in the first quarter of the year.
• Lilly has done this before, and won without a ruling. In October 2024 it sued a Washington seller of research grade tirzepatide under that state's consumer-protection act (W.D. Wash., No. 2:24-cv-01719), after a cease-and-desist letter went unanswered. The case settled in May 2025, with the court keeping jurisdiction to enforce the agreement. The research-seller campaign of 2026 is the 2024 case repeated at scale.

None of that is in question. What follows is.

Question one: injury without a product

A plaintiff in federal court has to show it was hurt. Lilly's complaints plead three kinds of harm. First, that people are switching from Lilly's FDA-approved medicines to illegal retatrutide products, costing it sales of tirzepatide and orforglipron, which are different molecules. Second, that sellers are poisoning the well for a retatrutide medicine Lilly hopes to sell after an approval it has not yet applied for. Third, that if people have bad experiences with black-market products they may blame Lilly.

The evidence pleaded for the first theory is two anonymous Reddit posts, neither of which mentions any defendant. The second theory is, in Lilly's own words, about a future retatrutide medicine, if approved. The third is pleaded on information and belief and begins with the word if.

The one defendant that has answered put the problem plainly. Its motion to dismiss (E.D. Tex., No. 1:26-cv-00347, filed 2 October 2026) opens with Lilly's own pleading:

Lilly does not sell retatrutide, and on its own allegations it cannot. … Lilly seeks damages for lost sales due to a product it does not and cannot lawfully sell.

The motion argues that every theory of injury runs through choices made by other people: whether a buyer of a research-labeled product uses it anyway, whether that buyer would have qualified for and been prescribed a Lilly medicine instead, whether an adverse event will ever occur and be blamed on a company whose name is on no product. It argues that if selling a different molecule to the same consumer pool makes a company Lilly's competitor, then so is every diet-supplement maker. And it argues that the eight state statutes each require an actual loss, proximately caused, that Lilly has not pleaded.

These are not novel arguments, and that is what makes them serious. Lilly has lost on them before, in its own cases, against defendants who were selling Lilly's own molecule:

• In February 2026 a federal court in California dismissed Lilly's suit against a telehealth company with prejudice, holding that the physician's prescribing decision, not [the defendant's] advertisements, is the proximate cause of a person using a compounded product, and that Lilly had pleaded nothing approaching the one-to-one relationship between its lost sales and the defendant's sales that the Supreme Court's Lexmark test asks for (C.D. Cal., No. 2:25-cv-03570, 3 February 2026).
• In April 2026 a federal court in Houston dismissed Lilly's Lanham Act claims against a large compounding pharmacy for the same reason, finding no such relationship, while letting the eight-state consumer-protection counts go forward past a different set of objections (S.D. Tex., No. 4:25-cv-03464, 29 April 2026). The same court, and another before it, held that Texas common law does not recognize an unfair-competition claim built on the Texas drug statute, a holding the Texas count in each of the new complaints has to survive.
• In October 2025 a federal court in San Francisco dismissed another Lilly suit for lack of standing, because the reputational injury rested on this lone internet post by an unidentified individual. Lilly amended, and the case was revived in part in April 2026 on state-law grounds; its Lanham Act conspiracy claims were dismissed again in September.

Where Lilly's standing has been upheld, the court has said why: the defendant was selling the same molecule, so each sale it made was plausibly a sale Lilly lost. A court in Texas said exactly that about a Novo Nordisk case in June 2026. The new suits ask courts to extend that reasoning to a molecule the plaintiff does not sell. They may; the question has not been decided. Lilly's answer to the motion is due in mid-November, and the court has set a conference for 30 November.

Lilly's strongest sentence, that no one may sell this molecule for human use, is also the defense's: if no one may sell it, Lilly has no sales of it to lose.

Question two: borrowed law, and where it is borrowed

Because the federal drug statute cannot be privately enforced, Lilly sues under state statutes that copy it. Whether that is allowed has divided the courts.

In Florida, a line of decisions in Novo Nordisk's and Lilly's own cases held that it is not: a state consumer-protection claim whose only wrong is selling an unapproved drug is, in substance, private enforcement of the federal Act, and is impliedly preempted under the Supreme Court's Buckman decision (M.D. Fla., Nos. 8:23-cv-1503, 3:23-cv-808 and others, 2023 to 2025). A Florida claim survived only where the seller had made an affirmatively false statement, such as calling a compounded product FDA-approved, that a court could judge without first deciding a question of federal drug law (M.D. Fla., No. 8:24-cv-2292, 17 April 2025).

In Texas, Louisiana and Mississippi, the Fifth Circuit took the opposite view in Zyla Life Sciences v. Wells Pharma of Houston (10 April 2025). Six states had made it illegal to sell a new drug not approved under section 505 of the federal Act, and a manufacturer sued a compounder under them. The court held there was no conflict to preempt, because the state statute makes federal law its own, quoting a 1949 Supreme Court case. The Ninth Circuit, which covers California, had reached the opposite conclusion in 2022. The compounder asked the Supreme Court to resolve the split. The Court invited the Solicitor General's views; the government said the Fifth Circuit was right at least for purposes of petitioner's motion to dismiss, called the disagreement between the circuits shallow and uncertain, and advised against review. The Court declined the case on 29 June 2026.

So the theory stands in the Fifth Circuit, is doubtful in the Ninth, and has been rejected by several district judges in Florida. Now look at where Lilly filed. Five of the six August cases are in Texas. Three of the five October cases are in Texas, and a fourth is in Louisiana, also in the Fifth Circuit. The one August case in California, in the Ninth Circuit, was the one case pleaded under the Lanham Act rather than state law, and it was the first to be dismissed. The Arizona case, also in the Ninth Circuit, is pleaded under the Lanham Act too.

Some of that is geography: the sellers are where they are. But a company that has litigated these theories in Florida and California knows which courthouses receive them well, and the pattern is consistent with that knowledge. It is a lawful choice, and a telling one. The eight-state template has not yet been tested against a seller of a molecule the plaintiff does not sell, in any circuit.

Question three: how these cases end

Of the six August suits, three are already over, each by a notice of voluntary dismissal with prejudice filed by Lilly before the defendant had responded: the medical spa chain on 11 September, and two Texas sellers on 15 and 16 October. CBS News reported on the day of filing that those same three defendants had taken down their retatrutide pages. In the Houston case, Lilly had told the court on 11 September that the defendant has failed to appear and that Lilly intends to move promptly for entry of default and default judgment. Five weeks later it dismissed instead. A default judgment would have been Lilly's for the asking; it chose a dismissal that bars it from suing that defendant again.

The Austin case shows the other side of the campaign. Lilly sued a limited company, then amended to add an entity or person doing business under that assumed or common name whose true legal identity is presently unknown, noting that it has been unable to ascertain the true identity of this defendant despite reasonable efforts. It is now asking the court for permission to take discovery before service, to find out who is behind the website. A reporter's email to the company bounced.

The compounding pharmacy is talking settlement. The one seller that hired counsel and filed a motion is the only case in which a judge will be asked to decide anything, and the earliest that could happen is the end of November.

This is the same pattern we described in our piece on FDA's warning letters: a body of outcomes that looks like law but contains almost no adjudication. Lilly told the press in September that its campaign against compounders and telehealth companies has produced more than a dozen permanent injunctions. Those are consent judgments, agreed between the parties. In July 2026 a federal judge in Indianapolis refused to enter one, because it was premised on a confidential settlement agreement that the Court has not seen; a judge in Washington state had done the same in June, and the parties withdrew the filing and dismissed the case. Courts are beginning to ask what they are being asked to sign.

Question four: who is sued

By Lilly's own count, 14,000 listings and 200 referrals. By the dockets, eleven defendants: a pharmacy in a Houston suburb, a spa chain, a clinic, a medical practice, and seven online sellers, one of them an individual trading under a business name, one of them a company Lilly cannot identify. The Lumberton seller is defended by a small firm; Lilly has four Kirkland & Ellis offices on its signature block. Lilly's own executive described the first wave as a start, and said six lawsuits is not going to be the solution to everything.

We do not know why these eleven. Lilly has not said, beyond the general description in its release, and we will not guess at motive. The record does let us say what the eleven have in common: they are small, they are mostly in the Fifth Circuit, and most of them did not fight. Three took down their pages and were released. One vanished. One is negotiating. The outcome for Lilly, in every case but one, is the conduct stopping without a court ever examining the theory that produced the complaint. Whether that is the purpose or the by-product of the selection, we cannot say. It is the result.

Question five: the other retatrutide case

There is a second retatrutide lawsuit in the federal courts, and Lilly is the plaintiff in that one too, against FDA. In November 2023 Lilly asked the agency to classify retatrutide as a biological product rather than a drug. The regulatory line is forty amino acids: a protein is an alpha-amino-acid polymer of more than forty. Retatrutide's backbone has thirty-nine, with a two-unit side chain attached, one unit of which is not an alpha amino acid. FDA counted forty and called it a drug. Lilly sued in September 2024. In September 2025 the court in Indianapolis agreed with FDA that the molecule is not a protein under the regulation, but held that FDA's refusal to consider whether it is analogous to one was arbitrary, and sent that question back to the agency. Lilly appealed; the Seventh Circuit heard argument on 24 September 2026 (No. 26-1301), and the case is pending. Lilly has said it intends to seek approval as a biologic in early 2027. This library's regulatory timeline has the 2020 rule that drew the forty-amino-acid line.

Hold the two cases side by side. In Indianapolis, Lilly argues that retatrutide should not be regulated as a drug at all. In Texas, Lilly's complaints define it as a new drug under eight state statutes, each of which forbids selling a new drug without an approval under federal law, meaning the drug-approval provision, section 505. Biologics are not approved under section 505; they are licensed under a different statute. The two positions are not contradictory today, because FDA's classification stands while the appeal is heard. But if Lilly wins its appeal, the statutes it is suing under would need a second look, and the first people to take that look would be the defendants. We raise it as a question, not a prediction.

What these cases will turn on

This is not legal advice, and no one should take it as a plan. It is a reading of the record, which shows fairly clearly where the pressure is.

1. Standing and causation. The first decision in any contested case will be whether a company can be injured, in the constitutional and statutory senses, by sales of a product it cannot sell. Lilly has lost that argument against sellers of its own molecule in two courts this year. The pending motion in East Texas is the first test against a seller of a different one.
2. Which circuit. Inside the Fifth Circuit, the borrowed-statute theory is good law after Zyla. Outside it, a defendant has the Florida decisions and the Ninth Circuit to cite, and the Solicitor General's own description of the question as unsettled.
3. Texas common law. Two Houston courts have already rejected the Texas count in Lilly's own cases. It appears, unchanged, in every new complaint.
4. The facts of the website. The theory is tested only if a defendant's conduct does not decide the case first. A seller whose complaint quotes a calculator, a kit, a comparison with approved medicines or an affiliate's testimony is in the same position as the recipients of FDA's letters, and no argument about standing changes that. The common mistakes in this library are the evidence list in these complaints.
5. Appearing. The single most consequential fact in this record is that most defendants did not respond. A theory that is never argued is never lost, and every unanswered complaint adds to a body of outcomes that the next complaint will cite.

Two popular ideas deserve a word because they appear in online discussion of these cases and would fail. The patent-law exemption for research use covers activity reasonably related to seeking regulatory approval; it has nothing to say about commercial sale. And the absence of a federal private right of action is not a defense to a state-law claim in the Fifth Circuit; Zyla settled that for now.

What to watch

• Lilly's response to the motion to dismiss in No. 1:26-cv-00347, due in mid-November, and the court's ruling after the 30 November conference. It will be the first judicial word on the theory.
• Whether the compounding pharmacy settles, and whether any settlement is filed as a consent judgment that a judge must approve.
• The Seventh Circuit's decision in No. 26-1301 on whether retatrutide is a biologic.
• FDA's own enforcement. The agency sent five more warning letters to research-labeled sellers in late August 2026, and a senator has publicly urged it to do more. Every letter FDA sends makes Lilly's private suits less necessary, and every suit Lilly files is, in part, a statement that the letters are not enough.
• The interim compounding policy for certain peptides that HHS and FDA sent for regulatory review on 14 October 2026. Whatever it says, it does not reach retatrutide, which FDA has said cannot be compounded, and it does not reach the research-use channel at all.

Warning letters are FDA's interpretation in particular cases, and may change. Complaints are a plaintiff's allegations, not findings. A motion to dismiss is a defendant's argument, not a ruling. Everything in this piece should be read with those three sentences in mind. We will update it as the dockets move, and every change will be dated on this page and listed in the corrections log if we got something wrong.

Frequently asked questions

Is it legal to sell retatrutide labeled for research use?

Not for human use, under any label: FDA has said so, and Lilly's complaints and the defense agree on that point. Whether a given seller's product was intended for human use is decided from the whole of its conduct, not from the label. Nothing in this piece suggests otherwise.

Has any court ruled for or against Lilly in the retatrutide cases?

No. As of 26 October 2026, three cases were dismissed by Lilly itself, one defendant could not be identified, one case is in settlement talks, one motion to dismiss is pending, and five cases are newly filed.

Why does Lilly sue under state law rather than federal drug law?

The federal Food, Drug, and Cosmetic Act can be enforced only by the United States. State statutes that copy it can be enforced privately in some circuits, including the Fifth, after the Zyla decision of April 2025.

Why no patent claims?

Lilly has not said. It holds patents on the molecule and did not assert them in any of the eleven complaints.

Sources & Further Reading

1. Complaint, Eli Lilly & Co. v. [compounding pharmacy], No. 4:26-cv-06563 (S.D. Tex. filed Aug. 12, 2026), Dkt. 1; Revised Joint Discovery/Case Management Plan, Dkt. 27 (Oct. 5, 2026); Order following scheduling conference, Dkt. 28 (Oct. 5, 2026); Order extending time to respond, Dkt. 30 (Oct. 20, 2026).
2. Complaint and Motion to Dismiss under Rules 12(b)(1) and 12(b)(6), No. 1:26-cv-00347 (E.D. Tex.), Dkts. 1 (Aug. 12, 2026) and 12 (Oct. 2, 2026); Order setting Rule 16 conference, Dkt. 19 (Oct. 19, 2026).
3. Plaintiff's Motion to Strike or Excuse Compliance with Discovery Planning Deadline, Dkt. 9 (Sept. 11, 2026), and Notice of Voluntary Dismissal with Prejudice, Dkt. 10 (Oct. 16, 2026), No. 4:26-cv-06562 (S.D. Tex.).
4. Notice of Voluntary Dismissal with Prejudice, Dkt. 11 (Oct. 15, 2026), No. 5:26-cv-05146 (W.D. Tex.).
5. Amended Complaint, Dkt. 6 (Aug. 31, 2026); Notice of Voluntary Dismissal, Dkt. 7 (Sept. 2, 2026); Motion to Allow Pre-Service Discovery to Determine Defendant's Identity, Dkt. 8 (Sept. 30, 2026), No. 5:26-cv-05147 (W.D. Tex.).
6. Notice of Voluntary Dismissal with Prejudice, Dkt. 6 (Sept. 11, 2026), No. 2:26-cv-02764 (E.D. Cal.).
7. Complaints filed Oct. 8, 2026: No. 5:26-cv-04146 (W.D. La.); No. 4:26-cv-08806 (S.D. Tex.); No. 3:26-cv-03514 (N.D. Tex.); No. 2:26-cv-07361 (D. Ariz.); No. 4:26-cv-01294 (N.D. Tex.).
8. Eli Lilly and Company. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. News release, August 12, 2026.
9. Complaint and Order approving settlement, Eli Lilly & Co. v. [research-grade seller], No. 2:24-cv-01719 (W.D. Wash. filed Oct. 21, 2024; order May 20, 2025).
10. Order on motion to dismiss, No. 2:25-cv-03570 (C.D. Cal. Feb. 3, 2026) (dismissing with prejudice for lack of Lanham Act standing).
11. Memorandum and Order, No. 4:25-cv-03464 (S.D. Tex. Apr. 29, 2026) (dismissing Lanham Act and Texas common-law counts; state consumer-protection counts proceed).
12. Orders on motions to dismiss, No. 3:25-cv-03534 (N.D. Cal. Oct. 24, 2025; Apr. 20, 2026; Sept. 8, 2026).
13. Zyla Life Sciences, L.L.C. v. Wells Pharma of Houston, L.L.C., No. 23-20533 (5th Cir. Apr. 10, 2025); petition for certiorari No. 25-257, Brief for the United States as Amicus Curiae (May 21, 2026); certiorari denied June 29, 2026.
14. Nexus Pharmaceuticals, Inc. v. Central Admixture Pharmacy Services, Inc., 48 F.4th 1040 (9th Cir. 2022).
15. Orders, Novo Nordisk Inc. v. [compounding pharmacy], No. 8:23-cv-1503 (M.D. Fla. Nov. 8, 2023, and later); No. 3:23-cv-808 (M.D. Fla. Jan. 30, 2025); Novo Nordisk Inc. v. [clinic], No. 8:24-cv-2292 (M.D. Fla. Apr. 17, 2025).
16. Buckman Co. v. Plaintiffs' Legal Committee, 531 U.S. 341 (2001); POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014); Lexmark International, Inc. v. Static Control Components, Inc., 572 U.S. 118 (2014); California v. Zook, 336 U.S. 725 (1949).
17. Eli Lilly & Co. v. Kennedy, No. 1:24-cv-01503 (S.D. Ind. Sept. 30, 2025); appeal No. 26-1301 (7th Cir., argued Sept. 24, 2026). Definition of the term "biological product", 85 FR 10057 (Feb. 21, 2020); 21 CFR 600.3(h)(6).
18. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. June 15, 2026.
19. CBS News. Report on two deaths submitted to FDA's adverse-event system after use of products represented as retatrutide. October 13, 2026.
20. Mealey's Litigation Report. Judge won't approve consent judgment reached by Lilly, others in tirzepatide suit (July 2026); Lilly, medical centers file stipulation of dismissal in compounded drug row (June 2026).
21. Holland & Knight. Peptides at a crossroads: what wellness providers need to know about HHS and FDA actions. October 16, 2026.
22. 35 U.S.C. § 271(e)(1); 21 U.S.C. § 337(a).

Cosmic Peptides. (2026, October 26). Lilly's retatrutide lawsuits: what the dockets say. Cosmic Peptides Research Library. Retrieved October 26, 2026, from https://cosmicpeptides.com/research/perspectives/lilly-retatrutide-lawsuits

@misc{cosmicpeptides_research_perspectives_lilly_retatrutide_lawsuits,
  author       = {{Cosmic Peptides}},
  title        = {Lilly's retatrutide lawsuits: what the dockets say},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = oct,
  url          = {https://cosmicpeptides.com/research/perspectives/lilly-retatrutide-lawsuits},
  urldate      = {2026-10-26},
  note         = {Last reviewed 2026-10-26}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Lilly's retatrutide lawsuits: what the dockets say
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/10/26
UR  - https://cosmicpeptides.com/research/perspectives/lilly-retatrutide-lawsuits
Y2  - 2026/10/26
LA  - en
ER  -